Published in:
01-04-2016 | Original Article
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
Published in: International Journal of Clinical Oncology | Issue 2/2016
Login to get accessAbstract
Background
We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD), the recommended dose (RD) and the safety profile of amrubicin (AMR) plus paclitaxel (PTX) combination regimen for patients with previously treated non-small cell lung cancer (NSCLC).
Patients and methods
PTX was administered at a fixed dose of 150 mg/m2/day on day 1 and AMR was intravenously administered at a starting dose of 25 mg/m2/day on days 1–3, and this was repeated every 4 weeks. Doses of each drug were planned as follows—level 0, 20/150; level 1, 25/150; level 2, 30/150; level 3, 30/180 AMR mg/m2 per day/PTX mg/m2 per day.
Results
Twelve patients were enrolled in this study. The dose-limiting toxicity (DLT) of the regimen was assessed during the first cycle. At level 1, all three patients developed a DLT due to grade 4 neutropenia lasting >4 days, grade 4 thrombocytopenia and grade 3 febrile neutropenia. Therefore, level 1 was considered the MTD and level 0 was selected as the RD. Objective responses were seen in two patients (response rate 16.7 %). Overall disease control rate was 91.7 %.
Conclusions
The combination of AMR and PTX is a feasible and well-tolerated regimen for the treatment of patients with previously treated advanced NSCLC. Although our study included a small number of patients, encouraging disease control and progression-free survival were achieved at the recommended doses. Further clinical trials are warranted.